Our Centres
Our Doctors
Your state: SA |
Our Centres
Our Doctors
Dr Marcus Dreosti
BSc, Hons LLB, MBBS (Hons) FRANZCR, Radiation Oncologist
Chief Medical Officer, GenesisCare Australia
For patients/carers
For doctors
BSc, Hons LLB, MBBS (Hons) FRANZCR, Radiation Oncologist
Chief Medical Officer, GenesisCare Australia
Locations
Clinical interests
- Breast cancer
- Prostate cancer
- Gynaecological cancer
- Oligometastatic cancer
- Palliative medicine
- Gastrointestinal cancer
Treatment techniques
- Stereotactic body radiotherapy (SBRT) / Stereotactic ablative radiotherapy (SABR)
- Deep inspiration breath hold (DIBH)
- Partial breast irradiation (PBI)
- Dominant intraprostatic lesion (DIL) boosting
- Volumetric modulated arc therapy (VMAT)
- Intensity modulated radiation therapy (IMRT)
Languages
Fluent
- English
Biography
Clinical interests include breast, prostate, gynaecological, gastrointestinal and oligometastatic cancers.
Dr Marcus Dreosti is the Chief Medical Officer of GenesisCare Australia, and a senior Radiation Oncologist practising in Adelaide, with subspecialty expertise in breast and prostate cancer.
Dr Dreosti holds honours degrees in both Law and Medicine from the University of Adelaide and Flinders University, respectively. He completed specialist training in Radiation Oncology at St Vincent’s Hospital in Sydney and the Royal Adelaide Hospital, followed by advanced clinical fellowships in Singapore and Darwin. He later joined Liverpool and Macarthur Cancer Centres in Sydney as a Staff Specialist, where he played a key role in establishing a stereotactic radiotherapy program and advancing breast cancer treatment.
With a strong focus on precision medicine, Dr Dreosti has led the integration of advanced radiation techniques and platforms, as well as being instrumental in introducing personalised prognostic tools for breast and prostate cancer into clinical use in Australia. He has also supported new technologies and offers treatments including stereotactic body radiotherapy (SABR), deep inspiration breath hold (DIBH) options, real-time tracking, volumetric modulated arc therapy (VMAT), and partial breast radiotherapy, enhancing treatment planning and outcomes for patients.
Dr Dreosti is actively involved in multidisciplinary care and clinical research, serving as Principal Investigator on several ongoing breast and prostate cancer trials. He is a regular attendee and speaker at national and international oncology conferences and has contributed extensively to professional education and training. He is committed to medical education, regularly teaching medical students, and has held academic appointments including Conjoint Lecturer at Western Sydney University School of Medicine. He is an Examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR) and was awarded the College’s highest award for sustained and outstanding contributions to education in Radiation Oncology.
In his role as Chief Medical Officer, Dr Dreosti oversees clinical governance and quality throughout GenesisCare Australia and has been dedicated over many years to improving the consistent delivery of evidence-based, high-quality clinical care across the entire GenesisCare network.
More information
- Wegener, E., Ng, M., Guerrieri, M., Showalter, T. N., de Leon, J., Ramani, S., Dreosti, M., … & Martin, J. (2025). Artificial intelligence impact on decision-making regarding short-term ADT with prostate radiotherapy: ASTuTE clinical trial interim results. Radiotherapy & Oncology, 206, S408–S410. https://doi.org/10.1186/s12885-025-13622-1
- Wegener, E., Ng, M., Guerrieri, M., Showalter, T. N., de Leon, J., Ramani, S., Dreosti, M., Martin, J., Tai, K. H., Spry, N., Roach, M., Woo, H., Turner, S., Joseph, D., Kneebone, A., Le, H., Scott, D., O’Toole, S., Denham, J., … Miller, A. (2025). A multicentre implementation trial of an artificial-intelligence-driven biomarker to inform shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: The ASTuTE protocol. BMC Cancer, 25(1), 250. https://doi.org/10.1186/s12885-025-13622-1
- Zissiadis, Y., Mann, B., Speakman, D., Saunders, C., Dreosti, M., … & Feetham, A. (2024, December). Changes in treatment recommendation for patients with ductal carcinoma in situ using a 7-gene predictive biosignature: Analysis of the PREDICT Australia study [Conference poster abstract]. San Antonio Breast Cancer Symposium (SABCS 2024), San Antonio, TX, United States. https://www.researchgate.net/publication/380310159_Abstract_PO4-22-05_Changes_in_Treatment_Recommendation_for_Patients_with_Ductal_Carcinoma_In_Situ_Using_a_7-Gene_Predictive_Biosignature_Analysis_of_the_PREDICT_Australia_Study
- Lai, K., Corry, J., Baxi, S. H., Burke, M., Dreosti, M. V., Ng, M., ... & Price, M. (2024). Optimizing Radiation Oncology: Integrating Clinical Decision Support and Automated Treatment Planning for Enhanced Quality, Consistency and Efficiency. International Journal of Radiation Oncology, Biology, Physics, 120(2), e635.
- Zissiadis, Y., Mann, G. B., Speakman, D., Saunders, C., Pike, C., de Viana, D., Bochner, M., French, J., Dreosti, M. V., Baron-Hay, S., Feetham, A., … & Reaby, L. (2023). OT3-11-03: The PREDICT Registry Australia: A prospective registry to evaluate the clinical utility of a 7-gene predictive biosignature on treatment decisions in patients with ductal carcinoma in situ. Cancer Research, 83(5_Supplement), OT3-11.
- Lai, K., O'Brien, P. C., Dreosti, M. V., Burke, M., Batchelor, N., Austin, M., ... & Hoy, L. (2023). Implementation of a Systematic, Digital Oncology Workflow for Patient Distress Screening in a National, Multi-Site Radiotherapy Outpatient Setting. International Journal of Radiation Oncology, Biology, Physics, 117(2), e402-e403.
- Zissiadis, Y., Mann, G. B., Speakman, D., Saunders, C., Pike, C., de Viana, D., Bochner, M., French, J., Dreosti, M. V., Baron-Hay, S., Feetham, A., … & Reaby, L. (2022, May). The PREDICT Registry Australia: A prospective registry to evaluate the clinical utility of a biomarker assay in treatment decisions in patients with DCIS following breast conservation surgery [Conference poster abstract]. International Journal of Radiation Oncology • Biology • Physics, 114(3 Suppl), E13. Poster presented at the Australasian International Breast Cancer Conference (AIBC 2022) and the American Society of Breast Surgeons Meeting 2022.
- Pryor, D. I., Turner, S. L., Tai, K. H., Tang, C., Sasso, G., Dreosti, M., ... & Martin, J. M. (2018). Moderate hypofractionation for prostate cancer: a user's guide. Journal of Medical Imaging and Radiation Oncology, 62(2), 232-239.
- Neville, K., Dreosti, M., Blakey, D., Latham, M., Izard, M. A., Young, S., ... & O’Brien, P. (2020). Adoption of hypofractionated radiation therapy for early breast cancer in private practice: the GenesisCare experience 2014–2106. Journal of Medical Imaging and Radiation Oncology, 64(1), 127-133.
- Hoyne, C., Dreosti, M., Shakeshaft, J., & Baxi, S. (2017). Comparison of treatment techniques for reduction in the submandibular gland dose: A retrospective study. Journal of Medical Radiation Sciences, 64(2), 125-130.
- Wegener, E., Ng, M., Guerrieri, M., Showalter, T. N., de Leon, J., Ramani, S., Dreosti, M., … & Martin, J. (2025, May). Artificial intelligence impact on decision-making regarding short-term ADT with prostate radiotherapy: ASTuTE clinical trial interim results [Conference presentation, Top 5% Award]. ESTRO 2025 – European Society for Radiotherapy and Oncology Annual Meeting, Glasgow, Scotland.
- Dreosti, M. (2024, August). Radiation options for recurrence following radical prostatectomy [Invited conference presentation]. Asia-Pacific Prostate Cancer Conference (APCC 2024), Melbourne, Australia.
- Dreosti, M. (2023, May). Personalised radiotherapy for DCIS [Invited conference presentation]. Royal Australasian College of Surgeons Annual Scientific Meeting (ASM 2023), Adelaide, Australia.
- Dreosti, M. (2023, October). ArteraAI Prostate Test [Invited conference presentation]. Urological Society of Australia and New Zealand (USANZ) South Australia Branch Meeting, Adelaide, Australia.
- Dreosti, M. (2023, September). Research workshop presentation [Invited conference presentation]. Australasian Society for Breast Disease (ASBD) Research Workshop, Sydney, Australia.
- Dreosti, M. (2022, October). Radiation oncology clinical updates and challenges workshop [Conference presentation]. Australasian Society for Breast Disease (ASBD) Annual Meeting, Brisbane, Australia.
- Dreosti, M. (2019, November). Optimising management of bladder cancer in the frail elderly [Invited conference presentation]. Clinical Oncology Society of Australia (COSA) Annual Scientific Meeting, Sydney, Australia.
- Royal Australian and New Zealand College of Radiologists (RANZCR)
- European SocieTy for Radiotherapy and Oncology (ESTRO)
- American Society for Radiation Oncology (ASTRO)
- Australian and New Zealand Head and Neck Cancer Society (ANZHNS)
- Australasian Society for Breast Disease (ASBD)
